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Abstract
Foods incorporating plant sterols (PS) reduce Low-density lipoprotein (LDL) on average
approximately 10%. PS with a higher lipid solubility may promote greater reductions. We
examined the cholesterol lowering effect of a novel triglyceride recrystallized phystosterol (TRP).
Twenty subjects (mean ± SD; age, 56 ± 10 years; BMI, 27 ± 5) with elevated LDL (>100 mg/dL)
participated in three 4-week phases; Phase I, 2% milk; Phase II, milk with 2.0 grams (g) free PS;
Phase III, milk with 2.0 g TRP. Before and after each phase two fasting blood draws were
obtained for determination of serum cholesterol. Between the 2% and TRP milk phases total,
LDL and High-density lipoprotein (HDL) cholesterol changed by -9.0% (p = .001), -11.0% (p =
.002) and -8.0% (p = .029) respectively: between the free PS and TRP milk phases total, LDL and
HDL cholesterol changed by -3.3% (p = .136), -2.3% (p = 1.00), -6.4% (p = .023) respectively.
Apo B concentrations resulted in a decrease of -6.9% (p = .048) between the free PS and TRP
milk phases and did not significantly change between the 2% and TRP milk phases.
Triglycerides and Apo A1 concentrations did not significantly change between any of the phases.
In conclusion, TRP can be effectively incorporated into a skim milk resulting in a significant
cholesterol lowering effect. (218 words)
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Chapter 1
Introduction
Lowering plasma low-density lipoprotein cholesterol (LDL-C) has been shown to lower
the risk of cardiovascular events. Typically lifestyle modifications including the consumption of
2.0 grams (g) phytosterol(s)/phytostanol(s) (PS) per day are recommended by the National
Cholesterol Education Program Adult Treatment Panel III and health care professionals to
facilitate the reduction in LDL-c (1). PS block the intestinal absorption of dietary and biliary
cholesterols (2), which result in reductions in total and LDL cholesterol (3) concentrations on
average 10%. Conventionally, consuming functional foods incorporating PS are a good way to
reach the recommended goal.
Although not all PS reduce LDL-c, and recommendations do not offer further guidance, it
is known that soy and wood PS with structural manipulations that increase lipid solubility and
incorporation into a food’s matrix. Both of these characteristics may promote further reductions
in cholesterol.
We examined the cholesterol lowering effect of a novel aided triglyceride recrystallized
phystosterol (TRP) in a matrix of skim milk. The primary hypothesis being that, as a monotherapy, the TRP milk matrix would lower cholesterol more effectively than an unaided free PS
milk matrix.

Chapter 2
2.0.0 Literature Review
2.1.0 Introduction:
High plasma cholesterol, predominantly plasma low density lipoproteincholesterol (LDL-c), is associated with increased heart disease and stroke, the leading
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causes of death in the United States. Therefore, lowering LDL-c is an important health
priority for individuals at risk for these conditions. Health care professionals
recommend that lifestyle changes (i.e., diet and exercise) be the first line of therapy for
cholesterol conscious individuals. To facilitate the lifestyle change process The National
Cholesterol Education Program Adult Treatment Panel III recommends a combination
diet therapy consisting of low saturated fat (<7%), low to moderate total fat (25-35%),
low cholesterol (<200 mg), 10-25 grams of soluble fiber and 2.0 grams of
phytosterols/phytostanols (PS) (4). Over the past 60 years a large number of studies have
consistently shown that foods with added PS, even as a mono-therapy, safely lower
serum total and LDL cholesterol without significantly affecting high density lipoprotein
cholesterol (HDL-c) and triglyceride concentrations (5).
Manufacturers have fortified many types of foods with PS providing individuals
who are trying to lower their cholesterol the ability to choose foods they prefer (6).
Recent reviews on foods with added PS address the incorporation of PS into a non-fat or
fat food matrix and whether PS characteristics can modulate their effect, (7, 8). The main
purpose of this review is to assess the cholesterol-lowering effect of PS incorporated into
specific foods with focus on the fatty acid composition of the food’s matrix. In addition,
assess the efficiency of PS based on the plant source/specific combination of PS and 3)
the PS’ structural form, and the subjects’ baseline LDL-c concentrations.
2.1.1 Mechanism:
PS lower plasma total and LDL cholesterol through a cycle that starts with the inhibition
of dietary and biliary cholesterol absorption in the intestine (3, 9-11). PS displace
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cholesterols first in the micelles (12) and second on the Niemann-Pick C1-like 1 transport
protein (13, 14). Resulting in less cholesterol transported into the enterocyte and
subsequently by the chylomicron (11, 13). All as evidenced by increased cholesterols in
the feces (15-17).
The cycle continues with hepatic adaptions, initiated to maintain cholesterol
homeostasis in response to the impaired cholesterol absorption. First, enzymatic
adaptions replace the bile acid and increase the hepatic cholesterol pools. Cholesterol
7alpha-hydroxylase (CYP7A), the rate-limiting enzyme responsible for bile biosynthesis,
is up-regulated in response to a reduced expression of farnesoid x receptor (FXR), a
known suppressor of the enzyme (18-21). Concurrently, hepatic 3-hydroxy-3methylglutaryl-coenzyme A (HMG CoA reductase), the rate-limiting enzyme
responsible for cholesterol biosynthesis is also up-regulated (22, 23). Second, to preserve
and increase the hepatic cholesterol pool, very low density lipoprotein (VLDL) output is
reduced (17, 24, 25), as evidenced by significant decreases in plasma apolipoprotein B
(26-29), and hepatic LDL receptors expression is increased (23, 24, 30).
Thus, if PS are consumed the cycle continues; biliary and dietary cholesterol
reabsorption/absorption is blocked, and they are discarded in the feces. Plasma
concentration of total and LDL cholesterol continue to be reduced as the cholesterol,
accumulated in the liver, is continuously shunted to the bile acid pathway. The final
outcome of this cycle is a more favorable lipid profile: the plasma total and LDL
cholesterol concentration is decreased and high-density lipoprotein cholesterol (HDL-c)
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and triglyceride (TG) concentrations are unaffected, leading to a higher HDL-c/LDL-c
ratio.
2.2.0 Methods:
2.2.1 Literature search:
To identify studies that examined the effects of PS on plasma cholesterol in
humans, PubMed was searched using the search criteria ((Plant sterol*[Title/Abstract])
OR

(Plant

stanol*[Title/Abstract])

OR

phytost*[Title/Abstract])

AND

(cholesterol*[Title/Abstract]), and limited to humans, clinical trials, randomized
controlled trials published in English. Additional articles were identified in reviews of
PS (31).
2.2.2 Selection criteria:
Trials that incorporated PS into foods to create functional foods were identified. A
study was eliminated if it: 1) did not describe the source or specific combination of the
PS used; 2) did not have a calculated LDL-c change or percentage change; 3) combined
dietary modification with foods containing added PS; 4) had subjects with non-lipid
disease states (i.e. diabetes); or 5) had >10% of subjects on lipid lowering drugs or
agents.
Studies were reported and evaluated as separate strata and labeled with a lower-case
letter after the publication year if they reported LDL-c changes for multiple time points,
functional foods or dosages. LDL-c percentage change was calculated by dividing the
delta change (post minus pre intervention) by the baseline LDL-c concentration. All
articles reporting the stated criteria were used in order to obtain a comprehensive
literature review.
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2.2.3 Data abstraction:
Data was abstracted from either the original articles or the article referenced for a
specific topic (i.e., PS used). The parameters extracted were (a) duration in weeks and
design (crossover or parallel); (b) at which meal the PS were consumed and frequency of
consumption; (c) dose of PS in grams per day; (d) reported percentage change in LDL-c;
(e) characteristics of the study population; (f) type of PS; (g) source and specific
combination of PS; (h) the reference (Table 1). If data was not reported in the article or
reference article the term “not reported” (NR) was used as a placeholder.
2.2.4 Data categorization:
Table 1 was primarily separated by food matrix. The strata within each matrix
category were separated further by the PS dosage. A total of 33 studies were identified
between the years 1998 and 2011 and 66 strata were isolated for evaluation.
2.3.0 Results and Discussion:
Based on the results presented in Table 1, PS consistently decreased serum LDLc. However, a few of the foods with added PS showed no effect on LDL-c, and when PS
were formulated into a pill (not reported in this review) minimal effects were reported
(32, 33). Although there is a fair amount of variability, studies generally show a dose
dependent LDL-c lowering effect with PS doses above 1 gram/day for a given food
(Figure 1). Some of this variability is likely due to differences in the food matrix,
especially the fatty acid composition. A number of other factors may also contribute to
variability in the LDL-lowering effect of PS such as source of PS, timing of PS ingestion,
duration of treatment, baseline LDL-c concentrations, background macronutrient
composition, and genetic differences among individuals. In this paper we specifically
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address the LDL lowering effects of specific foods with added PS and discuss the
importance of the nutrient composition of the food matrix.

Followed by a brief

assessment of how the PS plant origin and structure, as well as, how the subjects’
baseline LDL-c concentration may affect PS LDL-c lowering effectiveness.

Figure 1. LDL-c % change per gram/day of PS for individual food matrices.
To avoid a gap between 5.0 grams and 9.0 grams of PS/day one combination
matrix point was removed – (34), found a 17% decrease in LDL-c with 8.9 grams
of PS.
2.3.1 Food Matrix:
The most appropriate matrix for PS is thought to be one high in fat to enhance PS
solubility (35), however, low fat products may also be effective carriers (36). This may be
especially true with the addition of emulsifiers, such as lecithin, used to solubilize the PS
for dispersion throughout the matrix (37).
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In addition to carrying the PS, the food’s matrix also has the ability to enhance or
hinder the LDL-c lowering capacity through its fatty acid composition. Certain fatty
acids are known to lower cholesterol independent of PS thereby aiding in the PS’s ability
to lower LDL-c. Poly and monounsaturated fatty acids such as linoleic and oleic acids
found in soy oil and rapeseed oil generally lower cholesterol (4), whereas saturated fatty
acids on average increase LDL-c, with the exception of stearic acid which has a neutral
effect on LDL-c (38).
Just as fats known to decrease LDL-c may aid in overall ability of PS to lower LDL-c, fats
known to increase cholesterol concentrations, may hinder the hypocholesterolemic
effects of PS. For example, saturated animal fats, and trans fatty acids, acquired through
hydrogenation manufacturing processes, are known to independently increase LDL-c
concentrations (39).
It is understood that PS functionality is not solely impacted by the matrix of the
functional food itself. For instance, if the food is consumed with a meal or snack then the
interaction between the meal and the food with added PS becomes the “new” matrix
affecting functionality. In theory, a meal might provide additional cholesterol and fat
leading to greater bile release. Pairing foods with added PS with a meal should therefore
allow the PS to increase elimination of both cholesterol and bile in the feces, thereby
promoting greater LDL-c lowering.
Cholesterol lowering effects from studies published between the years 1998 to
2011 evaluating nine food matrices incorporating PS are discussed. These matrices
include margarine, mayonnaise, yogurt, milk, cheese, meat, grains, juices and
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chocolates.
Table 1. Food Matrices: The design, methodology, matrix, and LDL-c percent change, as
well as, subject and PS characteristics of references that utilized foods with added PS as
a cholesterol lowering mono-therapy.
Design

Xday

B/L/D

Dose
g/day

Reported
LDL-c%
∆

Bsl LDLc

Sex

Type PS

PS plant
source

Stanol
esters

Sitostanol 77
Campestanol
23

(28) a

Wood

(40) a

Wood

(40) b

Tall oil
Rapeseed oil

(41) e

Tall oil

(41) b

Soybean oil

(41) a

Reference

Margarine
4 wk.
crossover
13 wk.
parallel
26 wk.
parallel
3 wk.
parallel
3 wk.
parallel
3 wk.
parallel
3.5 wk.
crossover
4 wk.
crossover

2/3

w/
meal

0.8

NS

High

>50% M

2

NR

1.5

11%

High

NR

2

NR

1.5

11%

High

NR

NR
NR
NR
2

w/
meals
w/
meal
w/
meal

1.6

7%

High

<50% M

1.6

11%

High

<50% M

1.6

9%

High

>50% M

L+D

1.6

9%

Near
optimal

<50% M

Free
sterol
Free
sterol
Sterol
esters
Sterol
esters
Sterol
esters
Sterol
esters

2/3

w/
meal

1.6

6%

2

L+D

1.6

6%

2

B+D

1.8

5%

2

NR

2

10%

High

<50% M

NR

NR

2

9%

High

50% M

2

B+D

2

10%

Bdln
high

<50% M

NR

NR

2

8%

High

50% M

NR

NR

2.1

9%

Optimal

<50% M

4 wk.
crossover

2/3

w/
meal

2.4

10%

High

>50% M

Stanol
Ester

4 wk.
crossover

NR

NR

2.5

15%

Very
high

<50% M

Sterol
esters

NR

NR

2.5

8%

NR

NR

2.5

10%

NR

NR

2.5

10%

Very
high

<50% M

3

15%

High

<50% M

3

12%

High

<50% M

52 wk.
parallel
3 wk.
crossover
3 wk.
crossover
4 wk.
crossover
4 wk.
parallel
4 wk.
crossover
3 wk.
crossover

6 wk.
crossover
6 wk.
crossover
8 wk.
crossover
3 wk.
parallel
3 wk.
parallel

NR
NR

w/
meal
w/
meals

High
Bdln
high
Bdln
high

Bdln
high
Bdln
high
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>50% M
<50% M
<50% M

0% M
0% M

Stanol
ester
Sterol
esters
Sterol
esters
Sterol
esters
Sterol
esters
Stanol
esters
Sterol
ester
Free
sterols

Stanol
esters
Stanol
esters
Sterol
esters
Sterol
esters
Sterol
esters

Soybean oil

(42) a

Sitostanol 76
Campestanol
23

(28) b

Soybean oil

(43)

Soybean oil

(44)

Vegetable oil

(45) b

Tall oil

(46) b

Sitostanol 60
Campestanol
40

(29) a

Rapeseed oil

(46) a

Rice bran oil

(47)

Sitostanol 76
Campestanol
23
Soybean 60
Rapeseed 30
Sunflower 5

(28) c

(27) a

Tall oil

(48) a

Vegetable oil

(48) b

Soybean 60
Rapeseed 30
Sunflower 5

(27) b

Tall oil

(41) d

Tall oil
Rapeseed oil

(41) f

3wk.
parallel

NR

w/
meal

3

10%

High

>50% M

Sterol
esters

Soybean oil

(41) c

4 wk.
parallel

3

B+L+D

3

7%

Bdln
high

<50% M

Stanol
esters

Sitostanol 60
Campestanol
40

(29) b

2

NR

3

12%

High

NR

Wood

(40) c

2

NR

3

11%

High

NR

Wood

(40) d

2

L+D

3.2

NS

Rice bran oil

(49) b

2

L+D

3.2

NS

Sheanut oil

(49) c

2

L+D

3.2

13%

Soybean oil

(49) a

2

L+D

3.2

10%

Soybean oil

(42) b

2/3

w/
meal

3.2

10%

Sitostanol 76
Campestanol
23

(28) d

3

B+L+D

3.8

15%

Vegetable oil

(26) a

3

B+L+D

4

13%

Wood

(26) b

1

NR

0.3

12%SC

Soybean oil

(50) a

1

NR

0.4

11%SC

Soybean oil

(50) b

1

D

0.5

8%

Soybean oil

(51) a

1

D

0.5

NS

Soybean oil

(51) b

1

NR

0.5

15%SC

Soybean oil

(50) c

NR

NR

3.4

10%

Sitostanol 100

(52)

1

w/ meal

1

4%

Soybean oil

(2008a)
(53)

1

L

1.6

10%

Tall oil

(54) a

1

B

2

10%

Soybean oil

(55)

2

w/
meal

2

6%

Soybean oil

(53) b

NR

NR

<2

9%

Pine tree oil

(56) a

1

L

2.8

9%

Tall oil

(57) c

1

w/o
meal

2.8

5%

Tall oil

(57) d

2/3

B+L+D

3

14%

Vegetable oils

(58)

1

L

3.2

10%

Tall oil

(57) a

1

w/o
meal

3.2

7%

Tall oil

(57) b

12 wk.
parallel
26 wk.
parallel
3.5 wk.
crossover
3.5 wk.
crossover
3.5 wk.
crossover
3.5 wk.
crossover
4 wk.
crossover
8 wk.
parallel
8 wk.
parallel
4 wk.
parallel
4 wk.
parallel
2 wk.
crossover
2 wk.
crossover
4 wk.
parallel
6 wk.
parallel

4 wk.
crossover
6 wk.
parallel
4 wk.
parallel
8 wk.
parallel
6 wk.
parallel
4 wk.
parallel
4 wk.
parallel
4 wk.
parallel
4 wk.
parallel
4 wk.
parallel

Bdln
high
Bdln
high
Bdln
high
Near
optimal
High

50% M
50% M
50% M
<50% M
>50% M

Near
<50%
optimal
Near
<50%
optimal
Mayonnaise
Bdln
100%
high
Bdln
100%
high
Bdln
100%
high
Bdln
100%
high
Bdln
100%
high
Bdln
>50%
high
Dairy
Yogurt
Bdln
>50%
high
Bdln
NR
high
Near
>50%
optimal
High
Bdln
high
Bdln
high
Bdln
high
Near
optimal
Bdln
high
Bdln
high
Milk
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M
M

M
M
M
M
M
M

M

M

>50% M
<50% M
<50% M
<50% M
<50% M
<50% M
<50% M

Free
sterol
Free
sterol
Sterol
esters
Sterol
esters
Sterol
esters
Sterol
esters
Stanol
esters
Stanol
esters
Stanol
esters
Sterol
esters
Sterol
esters
Free
sterols
Free
sterols
Sterol
esters
Free
sterols

Free
sterols
Free
sterols
Stanol
esters
Free
sterols
Free
sterol
Sterol
esters
Sterol
esters
Stanol
esters
Sterol
esters
Sterol
esters

4 wk.
crossover
4 wk.
crossover
3 wk.
crossover
12 wk.
parallel
6 wk.
parallel
6 wk.
parallel

4 wk.
crossover

2

B+L

1.2

7%

High

<50% M

2

B+L

1.6

10%

High

<50% M

2

NR

2

8%

High

<50% M

2

w/
meals

2

7%

High

>50% M

NR

NR

2

11%

NR

NR

2

11%

2

L+D

1.5

15%

4 wk.
parallel

1

L

2.7

15%

6 wk.
parallel

2

w/o
meal

1.5

6%

Cheese
Bdln
<50% M
high
Bdln
<50% M
high
Other
Tortilla chips

Free
sterols
Free
sterols
Sterol
esters
Sterol
esters
Free
sterols
Free
sterols

Vegetable oil

(36) a

Vegetable oil

(36) b

Vegetable oil

(45) a

Vegetable oil

(59) a

Pine tree oil
Pine tree oil

(2006b)
(56)
(2006c)
(56)

>50% M

Free
sterols

Soybean oil

(60)

Meat
Bdln
100% M
high
Chocolate bars

Sterol
esters

Soybean oil

(61)

Sterol
esters

Soybean oil

(62)

Tall oil

(63) a

Tall oil

(63) b

Vegetable oils

(64)

Sterol
esters

Soybean oil

(65)

Sterol
esters

Soybean oil

(66) a

Sterol
esters

Vegetable oil

(45) c

Stanols

Soybean oil

(66) b

Free
sterols
+
stanols

Vegetable oil

(34)

High

High

<50% M

Juice/Drinks
3 wk.
crossover
3 wk.
crossover
8 wk.
parallel

8 wk.
parallel

3

B+L+D

1.8

10%

3

B+L+D

1.8

9%

2

B+D

2

9%

2

NR

3.2

15%

NR

w/as a
meal

High

>50% M

Bdln
>50% M
high
Bdln
<50% M
high
Combination
Croissants + muffins
Optimal

<50% M

Free
sterols
Free
sterols
Free
sterols

Cereal + bread + margarine
4 wk.
crossover

2.4

14%

High

>50% M

Milk + margarine
3 wk.
crossover

2

NR

NR

w/as a
meal

4

11%

High

<50% M

Cereal + bread + margarine
4 wk.
crossover

2.4

8%

High

>50% M

Margarine + oat drink
10 wk.
parallel

3

B+L+D

8.9

17%

Bdln
high

<50%M

NR, not recorded; B+L+D, breakfast lunch dinner; w/, with; w/o, without; wk., week(s);
X-day, times per day; PS, phytosterol/phytostanol; ∆, change; /, or; NS, no statistical
significance; SC, simple % change calculation.
2.3.1.a Margarine:
Over half the studies incorporating PS into foods used margarine. It is one of the
most effective food matrix; 19 strata showed a ≥10% decrease in LDL-c, and three strata
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showed a ≥15% decrease. Margarine has a high fat content supporting the PS solubility
and concentration in the matrix. Margarine is versatile, used to prepare and to
supplement foods, allowing for consumption with almost any meal or snack, which also
facilitates functionality. For these reasons margarine is a well-suited delivery matrix (35,
37).
Two of the three margarine products that decreased LDL-c by 15% were higher
in fat (70% and 74%) (26, 27) compared to the other (47%) (41). The 15% decrease in LDLc in response to low fat margarine is an anomaly considering that other low fat
margarine matrices (60% and 35%) resulted in significant LDL-c reductions of only 5%
and 6% respectively (43, 44). This discrepancy may be explained by the margarine’s fatty
acid composition. The successful low fat (47%) margarine matrix added 3.0 grams of PS
to a highly polyunsaturated fat matrix. The other two studies that reported 15%
decreases in LDL-c, either added 2.5 grams of PS to a 70% soy oil margarine matrix (27)
or added 3.8 grams of PS to a 74% rapeseed oil matrix (26). Other slightly less effective
products, resulting in LDL-c reductions of 13% and 9-10%, used linoleic and oleic fatty
acids in a 73% and 70% fat matrix respectively (42, 49) and LDL-c reductions of 11-12%
resulted when PS were added to an unreported percent rapeseed oil matrix (40).
A high proportion of saturated fats on the other hand may hinder a PS’s LDL-c
lowering capacity. Saturated fat made up 20% of the total fat in the 60% fat matrix
mentioned above to lower LDL-c 5%(44). In addition when 2.5 grams of PS were added
to a high saturated fat butter matrix, the resultant LDL-c concentrations were not
significantly lower than baseline although they were lower then butter alone (48). These
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results indicate that the specific fat make up of the high-fat matrix is an important
characteristic of the functional food.
Margarines can also contain trans fatty acids which may have negative effects on
serum lipid profiles by promoting a rise in plasma total and LDL cholesterol, as well as a
decrease in HDL-c (67). To date no PS margarine matrix, with a measureable amount of
trans fatty acids, has been manufactured and tested. This is most likely because
manufacturers have developed techniques to either filter or inhibit the formation of
trans fatty acids.
In summary, margarine is a common carrier of PS that consistently lowers LDL-c,
especially when it is comprised of a higher percentage of fat that includes a high
proportion of linoleic acid and/or oleic acid.
2.3.1.b Mayonnaise:
Only three studies and six strata have examined mayonnaise as a PS carrying
matrix, all with either rapeseed, soybean or safflower oil based matrices. Mayonnaise, a
fat-based spread like margarine, consistently contains 60% fat and shows significant
LDL-c lowering capabilities.
Two of the three studies used <1.0 gram of PS per day. Daily intake of 0.3, 0.4,
and 0.5 grams of PS resulted in 12, 11, and 15% decreases in LDL-c respectively (50). The
second study, which used only 0.5 grams of PS, lowered LDL-c by 8% (51).
Mayonnaise food matrices can be created with two varieties of fat, a
diacylglycerol (DAG) and triglyceride (TG), a characteristic that may affect PS
functionality. The two studies mentioned above were the only to report the use of a
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DAG PS matrix, which had a base of rapeseed, soybean and safflower oil. These two
studies were also the only (from the studies in this review) to have significant LDL-c
decreases with <1.0 gram of PS. The reports speculated first that a DAG matrix increases
PS solubility allowing for even distribution throughout the matrix, facilitating maximal
cholesterol displacement in the intestine. It was also speculated, that a DAG matrix may
hinder the rise in postprandial plasma triglycerides, decreasing Very Low Density
Lipoprotein Cholesterol synthesis and subsequently LDL-c concentration (68). Although
postprandial TG concentrations were not reported it should be noted when a low dosage
(0.5 grams) of PS was combined in a TG based rapeseed, soybean and safflower oil
mayonnaise matrix, LDL-c did not significantly decrease (51). To the contrary, when a
moderate dosage (3.4 grams) of PS was added to a TG based rapeseed oil matrix a 9%
decrease in LDL-c was achieved (52).
These results indicate that a DAG mayonnaise matrix may be more effective than
a TG matrix. Considering mayonnaise is the only functional food to report a matrix of
DAG, perhaps a DAG matrix would be equally as effective in other types of functional
foods, a consideration that warrants further investigation.
2.3.1.c Dairy: yogurt:
Yogurt products are a relatively new and effective PS delivery matrix. Five of six
studies and eight of ten strata, resulted in a significant decrease in LDL-c, with four
resulting in ≥10% decrease.
Similar to margarine and mayonnaise which are consumed with other foods,
when yogurt was consumed with either a breakfast or a lunch, 10% reductions in LDL-c
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were seen (54, 55), and when consumed three times a day with breakfast, lunch and
dinner there was a 14% reduction (58). However, not all yogurt products resulted in
significant LDL-c reductions when consumed with a meal. Two low fat (2%) yogurts,
with 1.0 gram of PS, reduced LDL-c concentrations by an insignificant 4 and 6% (53).
Even though an emulsifier (which was not identified) was used, it was speculated that
these results were the product of poor PS solubility in the matrix.
Yogurt also has an advantage over margarine and mayonnaise in that it can be
consumed independently as a snack. Snack foods are not consumed with excess
cholesterol and fat from a meal, however, they are more versatile to the consumer. One
of the more successful reduced fat (3.3%) yogurt products, when consumed with a meal,
resulted in an LDL-c reduction of 9%. When this same product was consumed without a
meal, it resulted in a reduction of 5%. In the same investigation a low fat (2.2%) yogurt
product, when consumed with a meal, resulted in an LDL-c reduction of 10%. When this
same product was consumed without a meal, it resulted in a reduction of 7% (57). It is
interesting to note that the reductions in LDL-c when yogurts were consumed
independently as a snack were only slightly less significant then when consumed with a
meal. It can be speculated that the composition of fat in the yogurt caused bile acid to be
released and excreted in significant amounts (69). Additional snack foods such as
hummus and cottage cheese could maintain similar characteristics, and promote
successful variety and versatility to PS containing snack foods.
2.3.1d Dairy: milk:
Cows’ milk PS matrices with PS have not been as prominently studied as other
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matrices, with only four strata and three studies. These milk products, although
showing ability to lower LDL-c, have not shown reductions of more than 10%.
All four milk matrix strata consisted of low fat products containing <2% fat (1.2% (36),
1.4% (45) and 1.8% (59)). Three of these milk products were consumed with a meal, and
one was consumed independently which did not seem to affect the magnitude of the
LDL-c reductions. All four of the milk matrices contained added poly and
monounsaturated fatty acids from vegetable oils rather than saturated milk fat alone
which may have enhanced the LDL-c lowering effect. A 7% decrease in LDL-c was seen
when 0.5 grams of monounsaturated fatty acids and 1.05 grams of polyunsaturated fatty
acids were added to create a 1.8% fat milk (59), and an 8% decrease in LDL-c was seen
when sunflower oil was added to create a 1.4% fat milk (45).
Even though these milk matrices contained added fatty acids known to enhance LDL-c
reductions, milks with added PS have yet to reduce LDL-c concentrations more than
10%. This might be caused by an insufficient percentage of fat (<2%) in the matrix.
Although speculative, if the percentage of fat of the matrix was increased to 2 or 3%, by
increasing unsaturated fatty acids, then the potential increase in PS solubility could lead
to greater decreases in LDL-c.
2.3.1.e Dairy: cheese:
Only one study and two strata have reported a cheese matrix with added PS.
LDL-c reductions of 11% were achieved with the incorporation of 2.0 grams of PS into a
hard and a soft cheese (56). Both were considered low fat cheeses yet they contained a
higher percentage of fat (10-15%) compared to other dairy PS foods. The cheeses had a
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predominantly saturated fatty acid composition yet the magnitude of LDL-c lowering
was similar to PS containing foods with a higher proportion of unsaturated fats. The
cheese matrices were likely able to effectively lower LDL-c because the amount of total
fat was enough to successfully incorporate the PS into the matrix, while the amount of
saturated fat was not enough to counteract the PS function. It is difficult to conclude on
the functionality of a matrix with only two reports, however, it seems that the slightly
higher percentage fat, even though predominantly saturated fat, promoted the LDL-c
lowering potential of the PS.
2.3.1.f Other:
Four additional foods have been studied: tortilla chips; ground meat; chocolates
and nonfat drinks. The PS enriched chips and meats both showed a 15% decrease in
LDL-c. The chips were fried in a 12% PS safflower oil which resulted in 1.5 gram of PS
per serving (60). Safflower oil is high in oleic acid and, as mentioned above, may
independently lower LDL-c. In order to maximize PS incorporation into the fatty acids
the PS were superheated with the TG from safflower oil. When this superheated PS TG
mixture cooled, the PS were recrystallized into the TG to from a TG recrystallized PS
matrix, which may enhance the LDL-c lowering capacity of the PS.
The meat was prepared by adding 2.7 grams of PS to an 11% fat ground meat. It
was consumed everyday for lunch. Generally ground beef has a moderate fat content
conducive to PS incorporation, but this specific ground beef had been manufactured to
contain less saturated animal fat myristic and palmitic acids and more polyunsaturated
vegetable fat linoleic acid. (61). The addition of PS to oil, used to fry foods, and to
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ground meat results in a relatively high decrease in LDL-c.
Stearic acid is found in chocolate and may have a neutral effect on LDL-c despite
its saturated nature (38). When a chocolate snack bar with added PS was consumed
between meals, LDL-c was only reduced by 6% (62). Although the methods used to
incorporate the PS were not reported, the result may be explained by the timing of
consumption, within 30 minutes of a meal instead of at a meal, and the small serving
size of chocolate consumed. This may have resulted in low amounts of fat and
cholesterol ingestion, reducing the PS ability to discard dietary and biliary cholesterol in
the feces. Considering these results and the potential presence of chocolate in the
American diet further investigations may increase the serving size to take better
advantage of the natural characteristics of chocolate and support the LDL-c lowering
capacity of this food.
When nonfat drinks were consumed three times a day with each meal or twice a
day with breakfast and dinner, 10 and 9% reductions in LDL-c were seen respectively
(63, 64). When a 1% fat drink was consumed with breakfast, lunch and dinner a 9%
reduction was seen (63). Although these results are significant, they continue the trend
seen with low fat PS milk in that the LDL-c reduction could be greater. If these drink
matrices were fortified with lecithin or poly and monounsaturated fatty acids to increase
the percentage fat then perhaps these added characteristics would first promote LDL-c
reduction and second disperse the PS efficiently through the matrix.
As the results indicate, PS can be added to almost any food matrix with or
without a high fatty acid composition. Modifications, however, can be made to increase
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LDL-c lowering efficiency. For instance the fatty acid composition of the matrix, the
consumption with a meal or as a snack and the timing of consumption all impact the
LDL-c lowering capacity. Therefore, the nature of the food and its potential matrix
should be considered in the development of PS enriched food products to maximize
functionality.
2.3.1.g Combinations:
Based on the literature, a variety of matrices provided cholesterol lowering
benefits. This variety is beneficial to consumers who have been advised to change their
lifestyle in order to reduce cholesterol and avoid medications. As more food products
are shown to efficiently reduce cholesterol, more options will come to market giving
consumers flexibility and a better chance for success.
Four articles and five strata examined LDL-c response when more than one type
of food with added PS was consumed per day. Two of these five strata provided ≤2.4
grams of PS per day, a daily dosage typical for one PS food. The LDL-c response for
these two trials was between 8-14% with matrices of whole-meal based starches paired
with an oleic canola oil based margarine (66). The three remaining strata had moderate
to high dosages of PS. The first strata was a combination of baked goods comprised of
20% fat and added oleic acid with a PS dose of 3.2 grams per day, the second strata was
a combination of low fat milk and vegetable oil based margarine with a PS dose of 4.0
grams per day, and the third strata was a combination of a vegetable oil based
margarine and a low fat oat based drink with 8.8 grams of PS per day. These reports
found LDL-c decreases of 15, 11 and 17% respectively (34, 45, 65).
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These results indicate that as foods with added PS are combined over the course
of a day, and as the PS dosage increases, the LDL-c response is more favorable (37, 70).
However, continued investigations should verify the efficiency and safety of combining
these products in attempts to control hypercholesterolemia.
2.3.2 Origin of PS:
In addition to the lipid composition of the food’s matrix, the PS plant source, or
origin, and any synthetic structural additions may impact the PS
effectives.

LDL-c lowering

Turning first to PS origin, different PS make-up a plants unique PS

composition. Origin and specific PS are presented in (Table 2). PS from one plant source
may be more effective over another (26, 47), however, the most common plants used to
obtain PS are soy and wood. Many studies also used a unique ratio of β. sitosterol and
campesterol, which are though to have increased LDL-c lowering capacity (28, 29)

Table 2. The percent range breakdown of the specific PS composition relative to the plant source.
Rapes Ricebr Shean
Soy
Wood
eed
an c
ut c
Specific PS
% range
45-55 75-85
50-55
β. Sitosterol
24meth
35-40
cycloartenol
30-35
α. Amyrin
Campesterol
20-30 1-5
30-35 10-15
Sitostanol
10-20
5-10
Cycloartenol
25-30
Lupeol
15-20
Stigmasterol
15-25
1-5
10-20
β. Sitostanol
Brassicasterol
5-10
Butyrospermol
10-15
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5-10
β. Amyrin
PS, phytosterols/phytostanols; α., alpha; β. beta.
c
ratios do not add to 100% due to trace PS that are not reported in the literature.

Soy PS and wood PS were studied alone in 20 and 19 strata respectively, and
combined with rapeseed PS in 22 and 21 strata respectively. The part soy or wood, part
rapeseed PS combinations ultimately had the same PS composition as soy or wood alone
and therefore were comparable (see Table 2). The soy and wood PS average LDL-c
responses were separated out for comparison and are presented in Table 3a. In
comparing the LDL-c responses there seems to be no striking difference between the two
PS ratios per subject’s baseline LDL-c level. The findings also show vegetable oils, which
may have atypical ratios of B. sitosterol and campesterol/(B. sitostanol and
campestanol), seem to lower LDL-c more effectively than the soy and wood PS. When
strata that used only B. sitosterol and campesterol / (B. sitostanol and campestanol) were
separated out the percent change in LDL-c was even greater then when soy, wood or
vegetable oil PS were used. These results support that a higher ratio of B. sitosterol to
campesterol / (B. sitostanol and campestanol) may enhance the reduction in LDL-c (26,
71).
β. sitosterol and campesterol are not, however, present in all plant sources, like
rice bran oil and sheanut oil (see Table 2). One of three strata, that used rice bran oil PS,
noted it also contained 1.0 gram per day of β. sitosterol and campesterol, and resulted in
a 9% reduction in LDL-c. The two remaining strata used a rice bran PS and a sheanut PS
and resulted in insignificant LDL-c reductions. These results and the literature (47, 49,
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72) suggest that not all plants contain a PS combination that will facilitate a decrease in
cholesterol. In addition to the lack of B. sitosterol and campesterol, these results may
also be linked to synthetic structural modification. All but one of the seven strata which
tested B. sitosterol and campesterol / (B. sitostanol and campestanol) used the free sterol
structure, the other six modified the PS to their stanol ester structure. Indicating that the
structural modification may have influenced the greater average reduction in LDL-c.
2.3.3 PS structure:
Structural changes to PS can be manufactured to create, what are commonly
thought to be more efficient PS. For example, stanols the saturated counterparts of the
free sterols, and PS esters the esterified counterpart of free sterols are both thought to be
more fat soluble and less absorbable, characteristics which increase cholesterol
displacement in the intestine. Overall, based on the results in Table 1, there are only
three main PS structures used in functional foods, free sterols, sterol esters, and stanol
esters, with 19, 33 and 13 strata reported in this review respectively. There are no cases
of free stanols. This is likely because free stanols have restricted fat solubility, inhibiting
the stanols incorporation into the matrix of the food, resulting in a decreased ability to
interfere with cholesterol and bile acid absorption. Once esterified however, the stanol
ester takes on even greater fat-soluble qualities than the sterol counterpart (73).

Table 3. The average LDL-c percent reduction from baseline for each plant origin (a) and type of
PS (b).
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g, gram; LDL-c, low density lipoprotein cholesterol; PS, phytosterol/phytostanol.
% change

Range g PS

a.
Soy (n=22)
Wood (n=21)
Vegetable oil (n=12)
B. sitosterol and
Campesterol PS (n=7)

9.3 ± 4.6%
-9.1 ± 3.2%
-10.8 ± 3.8%
-12.7 ± 4.6%
-

0.3 1.5 1.2 0.8 -

4.0
4.0
8.9
3.4

b.
-9.8 ± 3.8%
Free sterols (n=19)
0.5 - 3.0
Sterol esters (n=33)
0.3 - 4.0
9.3 ± 4.1%
Stanol esters (n=13)
0.8 - 4.0
11.8 ± 3.8%
Numbers are averages ± standard deviations
Rice bran PS, and Sheanut PS were excluded from the plant origin table due to an n size of thee
and one respectively.

To evaluate the LDL-c lowering efficiency of the PS structural differences, each structure
was averaged and presented in Table 3b. These results indicate that structurally
modified
stanol esters may have an advantage over both free sterols and sterol esters. These
results most likely occurred because not only are the sterol esters unable to be absorbed
but they also have a higher lipid solubility (17, 71, 74). However, it should be noted that
half the strata making up the stanol ester category used the PS B. sitostanol and
campestanol, which may have also played a roll in the LDL-c reductions. Often it is
thought that sterol esters also lower LDL-c more efficiently than free sterols. This
conclusion was not supported by the studies in this review.
2.3.4 Baseline LDL-c and PS therapy:
In addition to the two factors discussed in this review, it is thought that the
subject’s baseline LDL-c concentration may also play a role in the effectiveness of a PS
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therapy (75) (figure #2.). To evaluate the matter, the strata were separated by subjects’
baseline LDL-c level. A total of 2, 6, 28, 28 and 2 studies were classified into an LDL-c
baseline of optimal <100 mg/dL (<2.60 mmol/L), near optimal 100-129 mg/dL (2.60-3.34
mmol/L), borderline high 130-159 mg/dL (3.35-4.11 mmol/L), high 160-189 mg/dL (4.124.84 mmol/L) and very high >190 mg/dL (>4.85 mmol/L) (76) respectively. The average
decease in LDL-c for each classification was 9.5, 9.5, 8.8, 10.9 and 12.5% respectively. The
magnitude in LDL-c reduction, was also greater in subjects with a high or very high
baseline LDL-c and is shown in Figure 2. These findings support the use of PS as a mono
therapy for individuals with near optimal or borderline high LDL-c concentrations,
because the PS will be able to lower the individual’s LDL-c to an optimal range. Where
LDL-c, in individuals with high or very high baseline concentrations will likely be
reduced to the borderline high range thus necessitating other therapeutic methods, like
fiber and exercise, to lower LDL-c to an optimal range.

Figure 2. Total LDL-c concentration after PS intervention based on baseline LDL-c
concentrations.
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2.4.0 Conclusion:
It is clear that foods with added PS are an effective strategy to moderately lower
LDL-c. Many types of food matrices resulted in significant decreases in LDL-c,
especially when the nutrient composition of the matrix consisted of either poly or
monounsaturated fatty acids (i.e., linoleic and oleic acids), which may independently aid
in the reduction of LDL-c. Also B. sitostanol and campestanol, as well as, stanol esters
may have the potential to enhance the LDL-c lowering capacity. Milk, nonfat beverages
and chocolate bars are yet to show LDL-c decreases greater than 10% and therefore,
additional research should be conducted to determine how to successfully incorporate
the PS into these matrices.

Chapter 3
3.0.0 Methods
3.1.0 Experimental design
Men and women with moderately elevated plasma LDL cholesterol participated in three
4-week phases, to determine the effects of two different PS preparations delivered in a milk
matrix on plasma lipid responses. During phase I all subjects consumed 2% cows’ milk with no
PS. During phase II all subjects consumed skim cows’ milk containing 2.0 grams of unaided PS.
During phase III all subjects consumed fat-free cows’ milk containing 2.0 grams of triglyceride
recrystallized phytosterols (TRP). A first group took the TRP milk immediately after the
completion of phase II, and a second group took the TRP milk after a one month washout period
(non-testing phase).
To determine total cholesterol, LDL-c, HDL-c, triglycerides, and the total/HDL
cholesterol ratio, the average of two fasting blood draws was obtained at baseline and after each
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of the 4-week phases. A third fasting blood draw was made if duplicate LDL-c values varied by
more than 15%.
Subjects were asked to consume two 8 oz servings of the respective phase’s milk, one
serving at breakfast and one serving at dinner. Also to maintain their habitual diet and level of
physical activity throughout the entire period. A 3-day diet record (2 weekdays and 1 weekend
day) was obtained from baseline and at the end of each testing phase. If body weight fluctuated
more than 3.0 kg subjects were counseled by research dietitians for caloric adjustments in order to
maintain baseline weight.
3.2.0 Subjects
A total of 46 hyperlipidemic, weight stable men and postmenopausal women between the
ages of 35-70 years, were recruited from the local area (UConn Storrs, CT). Potential subjects
completed screening questionnaires (medical history, diet history and I-Pac). Participants were
excluded if they: had a diagnosis of hypertension, type I or II diabetes, liver, kidney, or other
metabolic or endocrine dysfunction; currently used cholesterol medications; or were known to
abuse alcohol or use tobacco products. Volunteers taking supplements known to affect serum
lipid levels such as anabolic steroids, fish oil, niacin, psyllium or NSAIDs were either excluded or
asked to maintain their habitual use. A fasting blood draw was performed and subjects with serum
LDL-c less than 100 or greater than 209 mg/day were excluded. Subjects were informed of the
purpose and possible risks of the investigation prior to signing an informed consent document
approved by the University’s Institutional Review Board. A total of 20 individuals met the study
criteria and finished the protocol. Baseline characteristics of subjects are shown in Table 4.

Table 4. Subject baseline characteristics. (n = 20)
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Values are mean ± SD
3.3.0 Milk Supplement
Phase I consisted of commercially available 2% cows’ milk obtained from the local Mountain
Dairy farm.
Phase II consisted of fat-free cows’ milk with 2.0 grams unaided (free) soy sterols.
Phase III consisted of fat-free cows’ milk, with 2.0 grams TRP. The TRP was derived from soy
and dispersed in
ultra-hightreatment. The milk
III were supplied
Inc, and consisted
free

(<0.5%

fat

/ 8.0 oz serving))
fat

milk

solids,

the milk prior to
Characteristics

Baseline

Age (y)
Gender (% male)
BMI (kg/m2)
Weight (kg)
LDL-c (mg/dL)
HDL-c (mg/dL)
Total Cholesterol
(mg/dL)
Triglycerides (mg/dL)
Fat Mass (kg)
Lean Body Mass (kg)

56 ± 9.6
65
27 ± 5.2
78± 16.9
134 ± 23.4
63 ± 21.2

temperature
for Phase II and
by GFA Brands,
of grade A fat-

219 ± 33.0

(<1.24 grams fat

109 ± 60.1
24 ± 11
501 ± 11

with added nonhigh

oleic

sunflower oil and sunflower lecithin.
3.4.0 Testing Protocol and Weekly Visits
At baseline and after each of the 4-week phases, subjects reported to the Human
Performance research laboratory (HPL) at the University of Connecticut for two consecutive,
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morning testing procedures. Subjects came 12 hours fasted and 24 hours in abstinences of intense
exercise, caffeine and alcohol consumption.
Testing day 1. The morning of testing day 1, subjects rested quietly for ten minutes in the
supine position, blood was then obtained from an arm vein and gathered in a serum separator,
serum, sodium citrate and Ethylenediaminetetraacetic Acid (EDTA) tube. Once blood was
obtained a series of anthropometric measures were taken including height, by averaging three
subsequent measures taken with a dual reading height rod (only at baseline); weight, by a digital
scale; and body composition, through dual-energy X-ray absorptiometry (Prodigy, Lunar
Corporation, Madison, WI). Finally the 3-day diet record was handed in and reviewed, with the
subjects, by one of the dietetic staff, for accuracy.
Testing day 2. Subjects returned to the HPL either 24 or 48 hours after the first visit for
testing day 2. Subjects rested quietly for ten minutes in the supine position, blood was then
obtained from an arm vein and gathered in a serum separator tube. Subjects took home the new
weekly milk supply and weekly compliance recording sheet (documenting date and time milk
was consumed).
Testing day 3. If testing day 1 and day 2 LDL-c values varied more than 15%, then
subjects returned to the HPL for testing day 3. Subjects rested quietly for ten minutes in the
supine position, blood was then obtained from an arm vein and gathered in a serum separator
tube.
Weekly visits. Subjects also checked into the HPL weekly (not fasted) during each testing
phase. At this time subjects were given a week supply of milk supplement and weekly
compliance recording sheet, their weight was taken, a questionnaire regarding changes in lifestyle
habits (dietary, supplement and physical activity changes) was filled out, finally the previous
week’s compliance recording sheet was handed in and verbal compliance was obtained.
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3.5.0 Analysis
Whole blood was collected into a serum separator, serum, sodium citrate (chilled) and
EDTA (chilled) tube. The serum separator and serum tubes clotted at room temperature and then
centrifuged with the chilled EDTA tube at 1600 x g for 15 minutes at 4°C, the sodium citrate tube
was centrifuged at 2000 x g for 30 minutes at 4°C. The serum separator was sent to a certified
medical laboratory (QUEST Diagnostics, Wallingford, CT) for determination of total cholesterol,
HDL-C, TG, and calculated LDL-c concentrations; LDL-c was calculated indirectly using the
Friedewald equation (77). The serum, sodium citrate and EDTA were aliquoted and stored in an 80°C freezer for later analysis. Diet records were analyzed for energy and nutrient composition
and monitored for dietary maintenance using nutrient analysis (NUTRITIONIST PRO,
Version 1.3, First Databank Inc, The Hearst Corporation, San Bruno, CA).
Apolipoprotein A1 was analyzed from sodium citrate plasma (200 fold dilution) by
ELISA (Innovative Research, Novi, MI), with sensitivity of 100 ng/mL, intraassay coefficient of
variation (CV) of 3.8% and interassay CV of 8.0%. The assay wavelength was read at 450 nm on
a Molecular Devices VERSAmax tunable microplate reader.
Apolipoprotein B was analyzed from sodium citrate plasma (20,000 fold dilution) by
ELISA (Innovative Research, Novi, MI), with sensitivity of 20 ng/mL, intraassay coefficient of
variation (CV) of 4.9% and interassay CV of 10.7%. The assay wavelength was read at 450 nm
on a Molecular Devices VERSAmax tunable microplate reader.
3.6.0 Statistics
Only subjects who completed the intervention and were compliant were analyzed. Means
and SD were computed and distributions for all dependent variables were examined for
approximate normality. Analysis of variance (ANOVA) was used to determine significant
differences over time and associations between variables. Bonferroni correction (or LSDequivalent) was used for all pair-wise comparisons. Covariate analysis was explored to determine
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if certain variables produce a significant covariate F score, for these instances ANCOVA with
multiple covariates with the model above was used. Significance was set at p≤0.05.

Chapter 4
4.0.0 Results
Compliance was 98.8% for all subjects, and did not differ between phases. The three milk
products were well tolerated, and no adverse side effects were reported. The subjects’ physical
activity, body mass and composition, and blood glucose and insulin did not significantly change
during any of the study phases. Nutrient intake was not significantly different between study
phases. Baseline dietary composition is presented in Table 5. Baseline lipids are presented in
Table 4.
Table 5. Baseline nutrient analysis.
Dietary Nutrients

Baseline

Kilocalories (Kcal/day)
Protein (g)
Carbohydrate (g)
Total Fat (g)
Saturated Fat (g)
Monounsaturated Fat (g)
Polyunsaturated Fat (g)
Trans Fatty Acid (g)
Dietary Fiber (g)
Cholesterol (mg)

2006 ± 675
92 ± 31
215 ± 76
81 ± 34
28 ± 14
21 ± 8
11 ± 6
0.6 ± 0.6
18 ± 6
329 ± 166

Values are mean ± SD.
Comparison of the lipid panel between phases is presented in Table 6. Plasma lipids did
not change significantly between the baseline and control phases (2% milk).

There were

significant reductions in total and LDL cholesterol between the 2% milk and both the free PS
milk (-5.9%, -9.0%) and the TRP milk (-9.0%, -11.%) respectively. Surprisingly, although the
effect sizes were small, there were significant reductions in HDL-c between the TRP milk and
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both the 2% milk (-8.0%) and the free PS milk (-6.7%), however, there was not a significant
difference between the TRP milk and baseline. There were no significant changes in total and
LDL cholesterol between the free PS milk and the TRP milk phases. There were also no
significant changes in triglycerides, LDL/HDL cholesterol ratios, and total/HDL cholesterol ratios
between any of the phases.

Table 6. Average plasma lipid values after each phase.
Parameter

P1
2% milk

P2
Free PS
milk

P3
TRP milk

P1 vs. P2
P1 vs. P3
P2 vs. P3
mean difference mean difference mean difference
p value
p value
p value
95% CI
95% CI
95% CI
Cohen’s d
Cohen’s d
Cohen’s d
Total
-13.2
-20.2
-7.0
cholesterol
223.6 ±
210.4 ±
203.4 ±
.039
.001
.136
33
33
35
(mg/dL)
(-25.8, -0.50)
(-33.1, -7.2)
(-15.3, 1.3)
.4
.6
.2
LDL-c
-12.4
-15.2
-2.8
(mg/dL)
138.3 ±
126.0 ±
123.1 ±
.019
.002
1.000
23
23
24
(-23.2, -1.6)
(-25.6, -4.7)
(-11.3, 5.7)
.5
.7
.1
HDL-c
-0.9
-5.1
-4.2
(mg/dL)
1.000
.029
.023
63.8 ± 21 62.9 ± 20 58.9 ± 19
(-4.6, 2.9)
(-9.8, -0.03)
(-8.0, -0.4)
.0
.2
.2
Triglycerides
0.4
0.5
.1
106.9 ±
107.4 ±
(mg/dL)
1.000
1.000
1.000
107.3 ± 7
68
67
(-24.1, 24.9)
(-18.6, 19.6)
(-18.6, 19.8)
.0
.0
.0
LDL/HDL
-0.1
-0.1
0.1
2.41 ±
2.21 ±
2.29 ±
cholesterol
1.000
.144
1.000
ratio
0.9
0.9
0.82
(-0.4, 0.2)
(-0.4, 0.2)
(-0.2, 0.3)
.2
.1
.0
Total/HDL
-0.2
-0.1
0.1
cholesterol
3.79 ±
3.82 ±
3.92 ±
.091
.126
.082
1.1
1.1
1.1
ratio
(-0.5, 0.1)
(-0.5, 0.3)
(-0.2, 0.3)
.2
.1
.1
Values are means ± SD; (p<0.05) using ANOVA repeated-measures and
Bonferroni adjustments
P1, Phase 1; P2, Phase 2; P3, Phase 3; 95% CI, 95% confidence interval.
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Apolipoprotein B (apo B) values resulted in a significant decrease between the free PS milk and
the TRP milk of -7 mg/dL. The apo A1 values, on the other hand, showed no significant change
between any of the milk phases. The apo A1/apo B ratio tended to be higher in the free PS milk
and TRP milk when compared to the 2% milk, 5.9% and 6.6% respectively, although not
significantly (Table 7).
Table 7. Average Apolipoprotein values after each phase.
Parameter

P1
2%
milk

P2
Free
PS
milk

P3
TRP
milk

P1 vs. P2
P1 vs. P3
P2 vs. P3
mean difference mean difference mean difference
p value
p value
p value
95% CI
95% CI
95% CI
Cohen’s d
Cohen’s d
Cohen’s d
po B
0.6
-6.33
-7.0
(mg/dL)
99.8 ± 100.4 93.5
.872
.104
.048
23
± 22 ± 21
(-6.5, 7.6)
(-14.1, 1.4)
(-13.7, -0.1)
.0
.3
.3
po A1
5.2
-0.5
-5.7
(mg/dL)
89.9 ± 95.0
89.4
.136
.865
.130
19
± 21 ± 13
(-1.8, 12.1)
(-6.6, 5.6)
(-13.1, 1.8)
.3
.0
.3
po A1/Apo B
0.1
0.1
0.0
0.99
1.00
ratio
0.94 ±
.282
.207
.923
±
±
0.28
(-0.1, 0.2)
(0.0, 0.2)
(-0.1, 0.1)
0.35
0.28
.2
.2
.0
Values are means ± SD; (p<0.05) using ANOVA repeated-measures
P1, Phase 1; P2, Phase 2; P3, Phase 3; 95% CI, 95% confidence interval.
PS and TRP milks (-6.6%), yet significantly different between the 2% and TRP milks (-6.5%)

These results indicate that 14 subjects had a more favorable LDL-c response to the TRP
milk compared to the free PS milk. The average percent change between free sterol and TRP milk
for these 14 subjects was -7.3% (Figure 3).
The graph also indicates that there were three subjects who did not respond to either the
free PS or the TRP milk, as indicated by LDL-c concentrations above zero for both phases. When
these non-responders were removed from the analysis the total and LDL cholesterol trends were
the same. The HDL-c trended on the other hand was not significantly different between the free
Table 8).
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Figure 3. Individual LDL-c response from free PS milk to TRP milk. Percent change from the
P1 control (2% milk) (n = 20).

The LDL-c results were also stratified according to the LDL-c classifications specified by
the U.S. Department of Health and Human Services (76) (Figure 4). All of the strata resulted in
reduced LDL-c in response to the two PS milks. Yet the magnitude in the reduction for the very
high group was on average greater than the borderline high and near optimal group 21, 9 and 6
mg/dL respectively. However, when compared to the free PS milk the TRP milk resulted in
greater percent changes in the near optimal and borderline high groups -68% (-3 mg/dL) and 42% (-3 mg/dL) respectively, where the very high group only resulted in a 2% (-0.5 mg/dL)
reduction.
Table 8. Average plasma lipid values after each phase for responders only (n=17).
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Parameter

Total
cholesterol
(mg/dL)

P1
2% milk

P2
Free PS
milk

P3
TRP
milk

222.3 ±
27

204.1 ±
28

197.9
± 30

138.8 ±
20

121.2 ±
17

119.3
± 19

64.2 ± 20

64.3 ± 21

60.0.
± 19

96.5 ± 43

93.4 ± 29

93.2
± 42

2.34 ±
0.7

2.05 ±
0.6

2.14
±
0.60

3.70 ±
0.9

3.38 ±
0.7

3.48
± 0.7

LDL-c (mg/dL)

HDL-c
(mg/dL)

Triglycerides
(mg/dL)

LDL/HDL
cholesterol ratio

Total/HDL
cholesterol ratio

P1 vs. P2
mean difference
p value
95% CI
Cohen’s d
-18.2
.000
(-27.0, -9.29)
.7
-17.6
.000
(-25.4, -9.8,)
1.0
0.1
1.000
(-2.9, 4.6)
.0
-3.2
1.000
(-26.2, 19.8)
.1
-0.3
.000
(-0.5, -0.1)
.4
-0.3
.001
(-0.5, -0.1)
.4

P1 vs. P3
mean difference
p value
95% CI
Cohen’s d
-24.4
.000
(-35.4, -13.3)
.9
-19.5
.000
(-28.6, -10.4)
1.0
-4.2
.018
(-7.8, -0.6)
.2
-3.4
1.000
(-21.7, 14.8)
.1
-0.2
.242
(-0.5, 0.1)
.3
-0.2
.595
(-0.6, 0.2)
.3

P2 vs. P3
mean difference
p value
95% CI
Cohen’s d
-6.2
.403
(-15.7, 3.3)
.2
-1.9
1.000
(-12.0, 8.1)
.1
-4.3
.066
(-8.7, 0.2)
.2
-0.2
1.000
(-23.4, 23.0)
.0
0.1
1.000
(-0.2, 0.4)
.2
0.1
1.000
(-0.2, 0.4)
.1

Values are means ± SD; (p<0.05) using ANOVA repeated-measures and Bonferroni
adjustments.
P1, Phase 1; P2 Phase 2; P3, Phase 3; 95% confidence interval.

The correlation between the baseline LDL-c value and the TRP LDL-c value is shown in
Figure 5. The correlation is highly significant (<0.0001) with a Pearson Correlation of 0.844.
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Figure 4. LDL-c responses to the milk products. Stratified according to the U.S. Department of
Health and human Services LDL-c classifications; ( ) represents LDL-c concentrations of “near
optimal” (100-129 mg/dL) (n of 9), ( ) represents LDL-c concentrations of “borderline high”
(130-159 mg/dL) (n=8), ( ) represents LDL-c concentrations of “high to very high” (>160
mg/dL) (n=3).

Figure 5. Correlation between baseline LDL-c values and the LDL-c response to TRP, (n=20).

Chapter 5
5.0.0 Discussion
In this study we confirmed that PS added to a non-fat milk matrix significantly lowers
both total and LDL cholesterol. The results of the current study’s free PS milk are in line with
other recent milk with added PS intervention studies, which show significant, yet below the
average (10%), reductions in LDL-c (36, 45, 59, 78). In fact, as far as we know, to date, no milk
with added PS has lowered LDL-c beyond the average 10%. Other PS added dairy products such
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as yogurts and cheese (56, 58), as well as, non dairy products such as margarine(26, 27, 41),
mayonnaise (50) and grains (34, 60, 65, 66) have trials which lower LDL-c well above the
average. These above average reductions are usually contributed to factors that increase the PS
lipid solubility into the food matrix and include using stanol esters (17). Rather than use stanol
esters our phase two milk intervention dispersed a fat-soluble novel TRP complex in a non-fat
milk matrix. As expected the results showed an above average LDL-c reduction (60).
These results were complemented with the trending reduction in apo. B after the TRP
milk intervention. There is one apo, B molecule per all non-HDL molecules (VLDL, IDL and
LDL). Reductions are commonly seen in trials that use the lipid soluble stanol ester (26, 28, 29).
These results indicate an actual reduction in number of lipoprotein in circulation, and may be
attributed to potential liver adaptions. The adaptions respond to the reduced dietary cholesterol
absorption and bile acid reabsorption, in an attempt to maintain the hepatic cholesterol pool. First
VLDL lipoprotein synthesis is reduced second LDL-c receptor expression is increased (17)
facilitating a larger uptake of LDL. The maintenance in apo. B after the free sterol milk
intervention despite the reduction in LDL-c indicates that rather than reducing the absolute
number of LDL particles, there may have been a change in particle sizes. Even though it is
established that significant changes in particle sizes do not occur with a sterol intervention, there
does seem to be a consistent insignificant trend showing a reduction in large LDL particles and an
increase in small particles (61, 79).
The TRP complex is a favorable addition to a non-fat milk matrix and showed a 7%
greater reduction in LDL-c when compared to the free PS non-fat milk in 14 of 20 subjects. The
variation in individual responses to PS is still unclear, however, it most likely do to the ability of
the PS to reduce enterocyte cholesterol absorption. It is commonly recognized that if the PS are
more lipid soluble then their ability to incorporate into the micelle and displace dietary and biliary
cholesterol is increased (12), ultimately reducing the absorption of cholesterols and reducing
LDL-c concentration. On the contrary the six individuals with an increase in LDL-c, in response
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to the TRP, may have an increased ability to absorb PS (11), and because the incorporation of
TRP in the micelles is greater these individuals may have absorbed more PS. The removal of the
PS from the intestine (3), then allows for an increased in cholesterol incorporation into the
micelle, resulting in an increased absorption and reabsorption of the cholesterols (11).
The individual variability in PS and cholesterol absorbability may have also been the case
for the three individuals who did not respond to either the free PS or the TRP. However, it is most
likely due to an up-regulation of whole body cholesterol synthesis in response to the decrease in
cholesterol absorption (80), which is indicative in individuals with an apo E4 allele phenotype
(71). When these three subjects were removed from the analysis the responders expressed an
above average 11 and 14 percent reduction in total and LDL cholesterol respectively when
comparing the TRP to the 2% milk phases.
The whole body cholesterol synthesis is also positively correlated with baseline
lathosterol concentrations. Lathosterol concentrations is a cholesterol precursor indicationg that
the higher the lathosterol concentration the higher the cholesterol concentration. A positive
correlation has also been associated with the baseline lathosterol concentrations and the LDL-c
percentage change after a PS intervention (71, 80). These associations therefore, link the baseline
LDL-c concentration with the LDL-c change after a PS intervention, which are also supported
here. Individuals with a very high baseline LDL-c concentration resulted in reductions twice as
high as the individuals with near optimal or borderline high baseline LDL-c concentrations.
An unexpected finding was the group’s average reduction in HDL-c after the TRP
intervention. The HDL-c was not reduced in our free PS milk phase, and to the best of our
knowledge no PS mono-therapy intervention has ever shown a significant reduction in HDL-c.
Only a few factors are known to reduce HDL-c concentration and include the dietary fatty acid
composition, particularly the consumption of trans fatty acids (81). The dietary characteristics in
our study population, as indicated by 3-day diet records during each phase, did not change in
trans fatty acid or any nutrient consumption. Therefore, it can be deducted that the triglycerides

36

used in the TRP matrix may have been manufactured in a way that formed a trans bonds.
Fortunately reducing the concentration of trans fatty acid in a food matrix has become more
conventional and would be relatively simple to implement (82). It was also noted that when only
the responders were analyzed the HDL-c during the TRP intervention was not significantly lower
than the free PS milk intervention. This conclusion can be explained by a concept discussed
above, individuals who do not respond to PS absorb the PS, which concurrently increases the
absorption of the trans fatty acids in the TG recrystallized to the TRP complex, and thereby
lowered HDL-c. Furthermore the responders, who do not absorb the PS did not absorb the trans
fatty acids as readily and their HDL-c was not significantly lower. The production of apo. A1,
which is associated with the HDL molecule was also not reduced in response to the TRP milk
intervention, when all subjects were analyzed. These results indicate that the TRP complex did
not increase the atherosclerotic risk (83) in responders to the TRP milk intervention.

Chapter 6
6.0.0 Conclusion:
Our results show that replacing 16 oz of 2% milk with 16 oz of non-fat milk with 2.0 g of
added novel phytosterols in the form of TRP will significantly lower LDL-c above the average
LDL-c reduction of 10%. Further study is needed to elucidate the relationship between the HDLc response and the fatty acids used in the triglyceride recrystallization.
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Appendix A. Informed Consent document
Consent Form for Participation in a Research Project
Principal Investigator: Jeff S. Volek
Study Title: Cholesterol Lowering Effects of Milk with Added Plant Sterols
Study Sponsor: GFA Brands, Inc.
Invitation to Participate
You are invited to participate in this study that will examine how daily intake of milk with added
plant sterols (plant cholesterol) affects the amount of cholesterol in your blood. Plant sterols are
known to decreases LDL cholesterol, but how this specific plant sterol contained within milk impacts
blood cholesterol levels has not been determined. The plant sterol will be added to milk containing
different levels of milk fat and you will be asked to consume the milk twice a day for 12 weeks.
What are the study procedures? What will I be asked to do?
This research study will take place at the University of Connecticut (UConn) in Storrs and will
last approximately 12 weeks. For this study, you will be required to follow your normal diet while
supplementing with the provided milk. We will require you to visit our lab at least 1 time per
week for the 12 week period. This is specifically what will happen during the research study.
Screening Visit: Your first visit will be a 30-minute screening visit, it will involve you filling out
a medical, nutrition, dietary supplementation, exercise history and menstrual (for women)
questionnaire. We will also determine your height, weight and blood pressure. We will ask you to
fast overnight for 12 hours for this screening visit so we can obtain a small blood sample (about
10 mL or 2 teaspoons) to determine your cholesterol level. All blood draws in the study will be
obtained by trained personnel. We are looking for men and postmenopausal women between 35
and 70 years of age who have moderately high levels or high levels of LDL cholesterol. You will
be excluded if any of the conditions below are true:
Exclusion Criteria:
1) You take cholesterol lowering medications.
2) Your body weight is more than 320 pounds.
3) You have diabetes.
4) You regularly use tobacco products.
5) You plan on changing your physical activity in the next 3 months.
6) Your have lost or gained more than 7 pounds in the last 3 months.
7) You consume alcohol more than 3 drinks/day or 18/week.
8) You have an allergy to milk or are lactose intolerant.
9) Your LDL cholesterol is greater than 210 mg/dL or less than 100 mg/dL at screening.
10) You have been diagnosed with heart disease or have high blood pressure.
If you have a blood cholesterol level over 130mg/dL you will need signed approval from your
doctor to participate in this study. If you are taking other medications or supplements known to
affect cholesterol levels we may ask you to discontinue use to allow for an adequate washout
period before beginning the study, or in some cases if you have been taking a consistent dose for
an extended period of time we will have you continue on the same regimen. Your doctor will
need to approve your decision to discontinue any medications or supplements and decide a
washout period for you.
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If you qualify based on the screening visit, we will schedule you to begin phase 1 of the study.
This is the sequence of events that will take place.
Baseline Visit 1: For the first baseline visit, we will be asking you to fast for about 12 hours
overnight before coming to the laboratory for blood testing and body composition scans. This
means no food or drink that contains calories (including coffee) but you should drink plenty of
water. We want you to be well hydrated during all tests. You must also avoid alcohol and
strenuous exercise for at least 36 hours prior to coming to the laboratory for testing. We will
obtain a small amount of blood from your arm using a needle. The amount of blood will be about
80 mL or 1/3 cup. We will also measure your body weight on a scale and your body composition
(fat, lean, and bone weight) using a machine that will expose you to a small amount of X-ray
radiation. You will lie quietly on a table while a scanning arm passes over your body from head
to toe. You must remain still for about 5 min during this test. A certified X-ray technician will
perform the scan. These tests will take about 1 hour.
Baseline Visit 2: We will ask you to come back to the laboratory on the following day (or as
close as possible to your previous visit) to obtain another blood sample (about 10 mL or 2
teaspoons). For this visit, we will also require that you fast overnight for 12 hours. The reason for
this second blood draw is to measure your cholesterol levels again to account for day-to-day
variability. If by chance the 2 cholesterol levels are more than 15% apart, we will ask you to
come back a third time to repeat the blood draw. This test will take about 30 min.
Milk Supplementation: After baseline testing we will provide you with the milk supplement.
You will be drinking 16oz/day (2 cups) of cow’s milk every day. You should try to drink one cup
with a morning meal and one cup with an evening meal. You will receive your first milk
supplement supply at the baseline blood draw, which should last about one week. You will be
expected to come in each week for a new milk supply and a weight check. You do not need to be
fasted during the milk pick up and weight check. We will also be in contact with you weekly to
check that you are consuming your milk and see how you are feeling. The milk supplementation
will continue for 12 weeks.
Follow-Up Testing: We will repeat the baseline testing again after 4, 8, and 12 weeks of milk
supplementation. At each of these time points, we will measure your body weight and body
composition, as well as 2 separate blood draws as described for Baseline Visits 1 and 2.
Diet: You will be asked to follow a diet that is as close to usual as possible over the 12 weeks.
We want you to continue your normal diet so that your weight will stay about the same
throughout the study. In order to help you with the diet and monitor compliance, we will ask you
to complete a 3-day food record before starting, and every 2 weeks for a total of 7 food records.
You will meet with a Registered Dietitian and receive instructions on how to complete the food
logs (writing down all foods and beverages you consume over the day). You will meet with a
Dietitian after each food record to go over the results and make changes accordingly to maintain
weight.
Blood Work: The primary markers we will measure in your blood will include cholesterol levels,
glucose, insulin, and fat soluble vitamins. The amount of blood taken being taken is relatively
small at any one visit. The total amount of blood taken over the entire 12 week project will not
exceed 410 mL (less than a pint).
Additional Testing Period. In addition to the 12 week intervention described above, we would
like to invite you to participate in an additional 4 week intervention period to study the effects of
a slightly different milk supplement containing plant sterols. The same protocols will be
followed as described in Baseline Visit 1 and Visit 2. Thus, we will be taking blood and
measuring your body weight and body composition before and after the 4 weeks of milk
supplementation. The total amount of blood we will obtain during the 4 visits to the lab will be
about 180 mL (3/4 cup) and the total amount of testing time will be about 3 hours.
What are the risks or inconveniences of the study?
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Managing Hyperlipidemia. The risk of elevated LDL cholesterol can primarily increase
chances of developing cardiovascular disease. Dietary modification is a preferred first line
of approach, and use of plant sterol has been shown to be effective in many people to
lower blood cholesterol levels. The nature of this project is such that a daily dose of plant
sterol will be provided to all subjects, thus there is a good chance you may see a decrease
in LDL cholesterol and therefore a decrease in risk for heart disease. If your starting LDL
cholesterol is greater than 130 mg/dL, you will need to obtain written permission from
your personal physician.
Milk with Added Plant Sterols. There have been a large number of research studies examining
plant sterols and they have been found to be well tolerated, especially at the dose of 2 g/day used
in this study. Their long-term safety has not been established. Plant sterols work by partially
blocking the absorption of dietary cholesterol into your blood, and therefore they often lower
blood levels of cholesterol in people. Some studies have shown that blood levels of fat soluble
vitamins may decrease, but this is unlikely to have any significant affect on your health in a 12
week period.
Blood Draws. Blood draws with a needle may cause discomfort at the puncture site and the
development of a slight bruise. You may also experience lightheadedness or fainting during the
blood draw. There is a slight risk of infection from these procedures. All possible precautions to
avoid infection will be taken including use of sterile disposable needles, drapes and gauze and the
practice of aseptic techniques during blood sampling. All blood samples will be obtained by
trained people. You should refrain from giving blood during the course of the study.
Body Composition. You will be exposed to a very small amount of radiation by the scanner used
to measure your body composition. Exposure to any amount of X-ray radiation, no matter how
low, may cause abnormal changes in cells. However, the body continuously repairs these changes
and the amount of radiation is very low in this study. The total exposure for a whole body scan is
approximately 125 times less than the average radiation from a standard chest x-ray. Thus, the
radiation levels are extremely low and the health risk minimal.
What are the benefits of the study?
The results of this study will help to determine the role plant sterols in milk have on responses to
cholesterol and general health, and therefore provide a potential therapeutic option for people
trying to manage their cholesterol levels within a healthy range. You will be provided with the
opportunity to talk with a Registered Dietitian regarding diet during the study. You will also learn
your body composition and will possibly improve health status. You will receive your pre and
post cholesterol levels and have this information to discuss with your doctor in order to plan for
follow-up care if needed. You may not benefit directly from this study.
How will my personal information be protected?
The following procedures will be used to protect the confidentiality of your data. The researchers
will keep all study records (including any codes to your data) locked in a secure location. The results
of this study will be kept in locked cabinets under the supervision of Dr. Volek. Research records
will be labeled with a unique code that will not contain any information that could be linked to your
identity. A master key that links names and codes will be maintained in a separate and secure
location. The master key will be destroyed after 3 years from study completion. All electronic files
(e.g., database, spreadsheet, etc.) containing identifiable information will be password protected. Any
computer hosting such files will also have password protection to prevent access by unauthorized
users. Only the members of the research staff will have access to the passwords. Data that will be
shared with others will be coded as described above to help protect your identity. At the conclusion
of this study, the researchers may publish their findings. Information will be presented in summary
format and you will not be identified in any publications or presentations.
You should also know that the UConn Institutional Review Board (IRB) and the Office of Research
Compliance may inspect study records as part of its auditing program, but these reviews will only
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focus on the researchers and not on your responses or involvement. The IRB is a group of people
who review research studies to protect the rights and welfare of research participants.
What happens if I am injured or sick because I took part in the study?
In the event you become sick or injured during the course of the research study, immediately
notify the principal investigator or a member of the research team. If you require medical care for
such sickness or injury, your care will be billed to you or to your insurance company in the same
manner as your other medical needs are addressed.
However, if you believe that your illness or injury directly resulted from the research procedures
of this study, you may be eligible to file a claim with the State of Connecticut Office of Claims
Commissioner. For a description of this process, contact the Office of Research Compliance at
the University of Connecticut at 860-486-8802.
Can I stop being in the study and what are my rights?
You do not have to be in this study if you do not want to. If you agree to be in the study, but later
change your mind, you may drop out at any time. There are no penalties or consequences of any
kind if you decide that you do not want to participate. You will be notified of all significant new
findings during the course of the study that may affect your willingness to continue.
You may be withdrawn from the study at any time. Conditions for such a withdrawal may include
missed appointments, non-adherence to study procedures, disruptive behavior during study
procedures, and/or adverse reactions to the supplement.
Who do I contact if I have questions about the study?
Take as long as you like before you make a decision. We will be happy to answer any question you
have about this study. If you have further questions about this project or if you have a researchrelated problem, you may contact the principal investigator, Jeff S. Volek at 860-486-6712. If you
have any questions concerning your rights as a research subject, you may contact the University
of Connecticut Institutional Review Board (IRB) at 860-486-8802.
Documentation of Consent:
I have read this form and decided that I will participate in the project described above. Its general
purposes, the particulars of involvement and possible risks and inconveniences have been
explained to my satisfaction. I understand that I can withdraw at any time. My signature also
indicates that I have received a copy of this consent form.

____________________
Participant Signature:

____________________
Print Name:

____________________
Signature of Person
Obtaining Consent

____________________
Print Name:
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__________
Date:

__________
Date:

